Showing 1961-1970 of 5063 results for "".
- Traffic-related Air pollution Linked to Facial Lentigeneshttps://practicaldermatology.com/news/traffic-related-air-pollution-linked-to-facial-lentigenes/2458707/High levels of traffic-related air pollution and air pollution-associated gases may increase risk of developing facial lentigenes, new research suggests. "While NO2 exposure is known to be associated with low lung function and lung cancer, the effect o
- Promius Receives FDA Approval for Sernivo Spray for Psoriasishttps://practicaldermatology.com/news/promius-receives-fda-approval-for-sernivo-spray-for-psoriasis/2458715/Dr. Reddy’s US subsidiary Promius Pharma received FDA approval for Sernivo (betamethasone dipropionate) Spray 0.05%. Sernivo Spray, a prescription topical steroid, is indicated for the treatment of mild to moderate plaque psoriasis in patients 18 years of age or older. The commercial launch
- Otsuka Licenses Pre-Phase 3 Topical Atopic Dermatitis Treatment to Medimetrikshttps://practicaldermatology.com/news/otsuka-licenses-pre-phase-3-topical-atopic-dermatitis-treatment-to-medimetriks/2458712/Otsuka Pharmaceutical Co., Ltd. and Medimetriks Pharmaceuticals, Inc. have entered into a licensing agreement granting Medimetriks exclusive development, manufacturing and commercialization rights for OPA-15406 in
- Alastin SkinCare Appoints Lynn Salo to Board of Directorshttps://practicaldermatology.com/news/alastin-skincare-appoints-linda-salo-to-board-of-directors/2458719/Lynn Salo is now a member of ALASTIN™ Skincare, Inc.’s board of directors. Ms. Salo has 27 years of experience with Allergan in the U.S., Canada, and Europe, including her role as Vice President, Sales and Marketing for the Facial Aesthetic
- Bristol-Myers Squibb Foundation Awards 8 Grants to Make Skin and Lung Cancer Screening More Accessible in High-Risk U.S. Communitieshttps://practicaldermatology.com/news/bristol-myers-squibb-foundation-awards-8-grants-to-make-skin-and-lung-cancer-screening-more-accessible-in-high-risk-us-communities/2458721/Bristol-Myers Squibb Foundation awarded eight grants totaling nearly $11.5 million to help make skin and lung cancer screening programs, care and patient support more accessible to underserved populations. The grants we
- Valeant: FDA Accepts BLA for Brodalumabhttps://practicaldermatology.com/news/valeant-fda-accepts-bla-for-brodalumab/2458726/The FDA has accepted for review the Biologics License Application (BLA) submitted by AstraZeneca in partnership with Valeant, for brodalumab injection, 210mg, a monoclonal antibody that targets the IL-17 receptor, in development for patients with moderate-to-severe plaque psoriasis. The FDA has a
- Vyome Biosciences: FDA Has Accepted IND for Investigational Acne Therapyhttps://practicaldermatology.com/news/vyome-biosciences-fda-has-accepted-ind-for-investigational-acne-therapy/2458728/The FDA has accepted from Vyome Biosciences an Investigational New Drug (IND) Application for the initiation of clinical studies for its lead program VB 1953, a topical therapeutic candidate for the treatment of moderate-to-severe acne. Vyome plans to start the Phase I clinical trials very soon.<
- Study: Women Younger than 40 at Melanoma Diagnosis Indoor Tanned Earlier, Morehttps://practicaldermatology.com/news/study-women-younger-than-40-at-melanoma-diagnosis-indoor-tanned-earlier-more/2458731/Melanoma among younger individuals is on the rise, and now new research suggests that initiating indoor tanning at an earlier age and more frequent tanning may be to blame. In the study, women younger than 40 when diagnosed with melanoma reported initiating indoor tanning at an earlier ag
- BioPharmX Corporation Appoints Craig A. Barbarosh to its Board of Directorshttps://practicaldermatology.com/news/biopharmx-corporation-appoints-craig-a-barbarosh-to-its-board-of-directors/2458734/BioPharmX Corporation appointed Craig A. Barbarosh to its board of directors. He will serve as an independent board member on the audit and compensation committees and will chair the nominating and corporate governance committee. Mr. Barbarosh is a member of the board of directors o
- Surgical Specialties Corporation Acquires FSSB Chirurgische Nadein GMBHhttps://practicaldermatology.com/news/surgical-specialties-corporation-acquires-fssb-chirurgische-nadein-gmbh/2458735/Surgical Specialties Corporation has acquired all shares of FSSB Chirurgische Nadein GMBH (FSSB) and affiliated entities. Terms were not disclosed. The acquisition will be immediately accretive to both Surgical Specialties' sales and adjusted EBITDA. FSSB was founded in 1995 by c